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Abstract
Compared to the age-matched men, the incidence of cardiovascular diseases is lower in
premenopausal but higher in postmenopausal women, suggesting the cardio-protective
role of estrogen in females. Although cardiac stem cells (CSCs) express estrogen recep-
tors, yet the effects of estrogen on CSCs remain unclear. In this study, we investigated the
potential role of estrogen in maintaining the quality of CSCs by in vivo and in vitro experi-
ments. For the in vivo study, estrogen deficiency was induced by ovariectomy in 6-weeks-
old C57BL/6 female mice, and then randomly given 17β-estradiol (E2) replacements at a
low dose (0.01 mg/60 days) and high dose (0.18 mg/60 days), or vehicle treatment. All mice
were killed 2 months after treatments, and heart tissues were collected for ex vivo expansion
of CSCs. Compared to age-matched healthy controls, estrogen deficiency slightly
decreased the yield of CSCs with significantly lower telomerase activity and more DNA dam-
age. Interestingly, E2 replacements at low and high doses significantly increased the yield of
CSCs and reversed the quality impairment of CSCs following estrogen deficiency. For the in
vitro study, twice-passaged CSCs from the hearts of adult healthy female mice were cul-
tured with the supplement of 0.01, 0.1, and 1 μM E2 in the medium for 3 days. We found that
E2 supplement increased c-kit expression, increased proliferative activity, improved telome-
rase activity, and reduced DNA damage of CSCs in a dose-dependent manner. Our data
suggested the potential role of estrogen in maintaining the quality of CSCs, providing new
insight into the cardio-protective effects of estrogen.
Introduction
Estrogen plays an important role in maintaining the homeostasis of various tissues/organs [1–
3]. Estrogen deficiency following menopause has been demonstrated to increase the risk of
cardiovascular diseases, osteoporosis, and diabetes [3, 4]. Premenopausal women have a lower
incidence of cardiovascular diseases compared to men of similar age, indicating the cardio-
protective effects of estrogen [5]. Although multiple observational studies have shown the
potency of hormone therapy in preventing cardiovascular diseases [6], recent clinical trials
have reported that hormone therapy exhibited no beneficial effect on the outcomes of
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cardiovascular diseases [1, 7]. These controversial results highlighted the necessity to confirm
the reality and further understand the mechanisms underlying the benefit of estrogen in car-
diovascular diseases.
Estrogen exerts its biological effects through receptors, including estrogen receptor alpha,
estrogen receptor beta, and G-protein-coupled ER, which are present in cardiac myocytes,
arterial smooth muscle cells, and endothelial cells [8, 9]. It has been reported that estrogen
mediates its cardio-protective effects by regulating lipid metabolism, vessel vasodilation,
angiogenesis, oxidative stress, and inflammation [8–12].
Recently, stem cells have been identified in almost all of the tissues/organs, and are known
to exhibit a pivotal role in maintaining the homeostasis of the body [13]. Emerging studies
have reported that estrogen receptors are expressed in a variety of stem cells, including embry-
onic stem cells, mesenchymal stem cells, and cardiac stem cells (CSCs) [14–17]. Estrogen can
regulate the differentiation of embryonic stem cells [18], inhibit the apoptosis of mesenchymal
stem cells [15], and enhance the functional benefit of mesenchymal stem cells for myocardial
repair [19].
CSCs, one of the most promising stem cell sources for myocardial repair have been tested
in clinical trials and showed beneficial effects [20–27]. It has been demonstrated that E2-treated
CSCs provide better cardio-protective effects [28]. However, it has not yet been well addressed
the role of estrogen in CSCs. Using an ovariectomy (Ovx) estrogen deficiency model in young
healthy female mice and in vitro experiments, we herein investigated the role of estrogen in
maintaining the quality of CSCs.
Materials and methods
Animals
For the in vivo study, 6-weeks-old female C57BL/6 mice were used. For the in vitro study, 10-
12-weeks-old female C57BL/6 mice were used. All experiments were approved by the Institu-
tional Animal Care and Use Committee of Nagasaki University, and the experiments were per-
formed following the institutional and national guidelines.
Ovariectomy and estrogen supplement
The 6-weeks-old female C57BL/6 mice were ovariectomized under general anesthesia. The
slow-release E2 pellets (Innovative Research of America, FL USA) of a low dose (LE2 group:
0.01 mg/60 days, n = 3), or a high dose (HE2 group: 0.18 mg/60 days, n = 3) were subcutane-
ously inserted to the mice soon after ovariectomy [29]. Mice received vehicle treatment follow-
ing ovariectomy (Ovx group, n = 3) or laparotomy alone (Control group, n = 3) were included
for comparisons. The doses of estradiol were selected based on previous studies [29, 30]. All
mice were sacrificed at 2 months after treatments. The uterus was excised and weighed, and
the atrial tissues were harvested for ex vivo expansion of CSCs.
Ex vivo expansion of CSCs
CSCs were expanded using a method similar to the previously described [31]. In brief, the
atrial tissues were minced into small fragments and cultured as “explants” on dishes coated
with 15 μg/ml fibronectin (CORNING). Stromal-like flat cells outgrew from the tissue frag-
ments in days and became confluent around 2 weeks after the initiation of culture. The out-
growth cells were collected and counted at 2 weeks and further expanded by general cell
passaging. All cultures were done in IMDM basic medium (Gibco) supplemented with 10%
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fetal bovine serum (HyClone), 100 units/ml penicillin G, and 10 μg/ml streptomycin (WAKO,
Japan), at 37˚C in a 5% CO2 incubator. Twice-passaged CSCs were used for evaluations.
Characterization of CSCs
The expression of c-kit in CSCs was evaluated by immunostaining as previously described [32].
In brief, twice-passaged CSCs (1×104/well) were cultured in 8-well chamber culture slides (Lab-
Tek, Thermo Scientific Nunc) coated with 15 μg/ml fibronectin for 3 days and then fixed with 4%
PFA for 10 min. After blocking, the cells were incubated with PE-conjugated rat anti-mouse c-kit
antibody (eBioscience). The nuclei were labeled with DAPI. The positively stained cells were
counted under a fluorescent microscope with 200-fold magnification in twenty randomly selected
fields, and the averages from 3 independent experiments were used for statistical analysis.
Immunostaining detection of the proliferation, telomerase activity, and
DNA damage of CSCs
The proliferative activity, telomerase activity, and DNA damage of CSCs were also detected by
immunostaining [32]. In brief, twice-passaged CSCs (1×104/well) were cultured on 8-well
chamber culture slides for 3 days and then fixed in 4% PFA for 10 min. After blocking, the
cells were incubated with primary antibodies against Ki-67 (Dako), telomerase reverse tran-
scriptase (TERT) (Abcam), and 53BP1 (Abcam), and followed by the appropriate fluores-
cence-conjugated secondary antibodies. The cell nuclei were labeled with DAPI. Positively
stained cells were counted as described above.
In vitro evaluations on the potential effect of E2 supplement to CSCs
We further performed in vitro experiments to confirm the potential effect of estrogen on
CSCs. Briefly, CSCs were expanded from the atrial tissues of 12-week-old healthy female mice
as described above. The same twice-passaged CSCs were cultured in 8-well chamber culture
slides with the supplement of 0, 0.01, 0.1, 1.0 μM E2 (Sigma-Aldrich) in the medium, as previ-
ously described [19, 28]. After 3 days of culture, immunostaining was performed to measure
the expression of c-kit, proliferative activity, telomerase activity, and DNA damage in CSCs as
described above.
Statistical analysis
All of the results are presented as the mean±SD. The statistical analysis was performed by
using one-way analysis of variance (ANOVA), followed by Tukey’s test as a post comparison
between groups (GraphPad Prism). Differences were considered significant when P<0.05.
Results
Estrogen supplement attenuated the uterine atrophy in mice after
ovariectomy
Estrogen deficiency was induced in six-week-old female mice by ovariectomy, and then given
low dose E2 (0.01 mg/60 days, LE2 group), high dose E2 (0.18 mg/60 days, HE2 group), or vehi-
cle treatment (Ovx group), respectively. Sham-operated mice were used as healthy controls
(Control group). After 2 months of treatments, mice were sacrificed and heart tissues were
used for ex vivo expansion of CSCs. Compared with the healthy controls, the uterine weight
was significantly decreased in ovariectomized mice (9.36±2.17 mg vs. 58.46±10.67 mg,
P<0.05, S1 Fig), confirmed the estrogen deficiency-induced atrophy. Compared to the Ovx
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group, the uterine weight was increased significantly in the HE2 group (108.23±27.61 mg,
P<0.05, S1 Fig), and partially in the LE2 group (27.4±10.35 mg, P = 0.16, S1 Fig).
Estrogen supplement significantly increased the number of CSCs in vivo
By using a defined protocol [31], we could easily expand CSCs from atrial tissues from all
mice. Although the yield of CSCs was lower in the Ovx group (1.84±0.39 x105 cells) than the
Control group (2.78±0.13 x105 cells), there was no significant difference between groups
(P = 0.08, Fig 1). Compared with the Ovx group, the yield of CSCs was almost 2-fold higher in
the LE2 group (3.58±0.08 x105 cells, P<0.05, Fig 1) and 3-fold higher in the HE2 group (5.72
±0.49 x105 cells, P<0.01, Fig 1).
Estrogen supplement significantly increased the c-kit expression of CSCs in
vivo and in vitro
The expression of c-kit in CSCs was higher in the Ovx group than the Control group, although
there was no significant difference between groups (1.13±0.19% vs. 0.62±0.05%, P = 0.07, Fig
2A). Interestingly, compared to the Ovx group and the Control group, the expression of c-kit
in CSCs was significantly increased in the LE2 group (4.77±0.52%, P<0.01, Fig 2A), and even
further enhanced in the HE2 group (7.71±0.71%, P<0.001, Fig 2A).
We also evaluated whether the E2 supplement would change the expression of c-kit in CSCs
from the hearts of healthy female mice in vitro. CSCs were cultured with E2 supplement at different
concentrations for 3 days and then used for analysis. Compared to the vehicle control (3.36±0.19%),
the expression of c-kit in CSCs was increased by the supplement with 0.01 μM E2 (4.47±0.53%,
p = 0.12), 0.1 μM E2 (5.68±0.65%, P<0.05, Fig 3A), or 1 μM E2 (8.09±0.98%, P<0.01, Fig 3A).
Estrogen supplement significantly increased the proliferative activity of
CSCs in vivo and in vitro
We evaluated the proliferative activity by immunostaining analysis on the expression of Ki-67.
The expression of Ki-67 in CSCs did not differ between the Control group and the Ovx group
Fig 1. The outgrowth of cardiac stem cells (CSCs) from the atrial tissues of mice. The outgrowth of CSCs was
evaluated 2 weeks after the initiation of culture. Control: sham-operated mice, Ovx: ovariectomized mice, LE2:
ovariectomized mice supplemented with low dose of 17β-estradiol (0.01 mg/60 days), HE2: ovariectomized mice
supplemented with high dose of 17β-estradiol (0.18 mg/60 days). All data are mean±SD from 3 independent
experiments (n = 3 for each group). �P<0.05, ��P<0.01.
https://doi.org/10.1371/journal.pone.0245166.g001
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(0.61±0.02% vs. 0.56±0.06%, P = 0.49, Fig 2B). However, compared to the Ovx group, the
expression of Ki-67 in CSCs was significantly higher in the LE2 group (2.94±0.14%, P<0.001,
Fig 2B) and the HE2 group (6.13±0.19%, P<0.0001, Fig 2B).
We also evaluated whether the E2 supplement would change the proliferative activity of
CSCs from the hearts of healthy female mice in vitro. Compared to the vehicle control (9.15
±0.19%), the expression of Ki-67 in CSCs was increased by the supplement with 0.01μM E2
(11.42±0.53%, p = 0.2), 0.1 μM E2 (15.65±0.65%, P<0.01, Fig 3B), or 1 μM E2 (17.51±0.98%,
P<0.05, Fig 3B).
Estrogen supplement significantly improved the telomerase activity and
reduced DNA damage of CSCs in vivo and in vitro
The telomerase activity and DNA damage of CSCs were evaluated by immunostaining analysis
on the expression of telomerase reverse transcriptase (TERT) and 53BP1, respectively. Com-
pared to the Control group, the expression of TERT in CSCs was significantly decreased in the
Ovx group (55.33±0.58% vs. 79.56±0.43%, P<0.0001, Fig 4A), but completely recovered in the
LE2 group (77.13±1.00%, Fig 4A) and the HE2 group (87.12±0.45%, Fig 4A). Although the for-
mation of 53BP1 foci was detected in more CSCs in the Ovx group than the Control group,
there was not significant between groups due to the small sample size (18.23±1.25% vs. 8.52
±3.64%, P = 0.06, Fig 4B). Compared to the Ovx group, the formation of 53BP1 foci in CSCs
was detected significantly less in either the LE2 group (4.52±0.25%, P<0.001, Fig 4B) or the
HE2 group (1.94±0.57%, P<0.001, Fig 4B).
We also evaluated the potential effects of E2 on telomerase activity and DNA damage of
CSCs from the hearts of healthy female mice in vitro. Compared to the vehicle control (78.83
±2.03%), the TERT-positive cells in CSCs was increased by the supplement with 0.01μM E2
(85.67±1.23%, P<0.05, Fig 5A), 0.1 μM E2 (89.96±0.53%, P<0.01, Fig 5A), or 1 μM E2 (94.34
±0.99%, P<0.01; Fig 5A) in the culture medium. In contrast, compared to the vehicle control
Fig 2. The expression of c-kit and Ki-67 in cardiac stem cells (CSCs). Immunostaining was performed to evaluate
the expression of c-kit (A) and Ki-67 (B) in twice-passaged CSCs. Representative images (upper) and quantitative data
(lower) are shown. The nuclei were labeled with DAPI. Scale bar: 20 μm. Control: sham-operated mice, Ovx:
ovariectomized mice, LE2: ovariectomized mice received a low dose of 17β-estradiol (0.01 mg/60 days), HE2:
ovariectomized mice received a high dose of 17β-estradiol (0.18 mg/60 days). All data are mean±SD from 3
independent experiments (n = 3 for each group). �P<0.05, ��P<0.01, ���P<0.001, ����P<0.0001.
https://doi.org/10.1371/journal.pone.0245166.g002
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(16.75±0.15%), the formation of 53BP1 foci in CSCs was decreased by the supplement with
0.01μM E2 (14.55±0.07%, P<0.001, Fig 5B), 0.1 μM E2 (13.78±0.21%, P<0.001, Fig 5B), or
1 μM E2 (12.65±0.06%, P<0.0001, Fig 5B) in the culture medium.
Fig 3. Dose dependency of the 17β-estradiol supplement on the expression of c-kit and Ki67 in cardiac stem cells
(CSCs) from healthy female mice. The expression of c-kit (A) and Ki-67 (B) in CSCs from healthy female mice were
evaluated by immunostaining after 3 days of culture with the supplement of different concentrations of 17β-estradiol
in the medium. Representative images (upper) and Quantitative data (lower). The nuclei were labeled with DAPI.
Scale bar: 20 μm. Control: sham-operated mice, Ovx: ovariectomized mice, LE2: ovariectomized mice received a low
dose of 17β-estradiol (0.01 mg/60 days), HE2: ovariectomized mice received a high dose of 17β-estradiol (0.18 mg/60
days). All data are mean±SD from 3 independent experiments (n = 3 for each group). �P<0.05, ��P<0.01.
https://doi.org/10.1371/journal.pone.0245166.g003
Fig 4. The telomerase activity and DNA damage of cardiac stem cells (CSCs). The telomerase activity and DNA
damage in twice-passaged CSCs were evaluated by immunostaining analysis on the expression of TERT (A) and 53BP1
(B), respectively. Representative images (upper) and quantitative data (lower) are shown. The nuclei were labeled with
DAPI. Scale bar: 20 μm. Control: sham-operated mice, Ovx: ovariectomized mice, LE2: ovariectomized mice received a
low dose of 17β-estradiol (0.01 mg/60 days), HE2: ovariectomized mice received a high dose of 17β-estradiol (0.18 mg/
60 days). All data are mean±SD from 3 independent experiments (n = 3 for each group). �P<0.05, ���P<0.001,
����P<0.0001.
https://doi.org/10.1371/journal.pone.0245166.g004
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Discussion
In the present study, we investigated the potential role of estrogen on CSCs. Using an ovariec-
tomy model in young healthy female mice, we demonstrated that estrogen deficiency-induced
quality impairment of CSCs, which could be completely recovered by the replacement with E2
following ovariectomy. In vitro, the E2 supplement in culture medium showed to improve the
telomerase and the proliferative activity and reduce the DNA damage of CSCs in a dose-
dependent manner. These data suggest that estrogen is likely required for maintaining the
quality of CSCs.
Estrogen is known to mediate oxidative stress, inflammatory response, and even the mobili-
zation/recruitment of stem/progenitor cells [8, 28, 33, 34]. However, it is still kept controver-
sial on the beneficial effects of estrogen on the heart. It has been reported that estrogen
increases the mortality post-myocardial infarction in mice [35]. In contrast, many studies have
demonstrated that estrogen delays the progression of cardiac hypertrophy and heart failure
and enhances the functional recovery of infarcted heart in mice and rats [33, 34, 36, 37], but
the underlying molecular/cellular mechanisms remain unclear. Therefore, we attempted to
investigate the potential role of estrogen on CSCs, a rare population of immature cells known
to be critical for maintaining the homeostasis of the heart and regulating the myocardial repair
after injury [20–27].
As the beneficial effects of estrogen to the heart may largely depend on the dosage of E2 [38,
39], we tested the effects of E2 replacement at a low dose (0.01 mg/60 days) and a high dose
(0.18 mg/60 days) to mice following ovariectomy. Estrogen deficiency in the ovariectomized
mice was confirmed by the presence of uterine atrophy, which was completely recovered by
the replacement with high dose E2. Although CSCs could be expanded easily from the atrial tis-
sues of all mice received different treatments, estrogen deficiency slightly decreased the yield
of CSCs with lower telomerase activity and higher DNA damage. All the estrogen deficiency-
Fig 5. Dose dependency of the 17β-estradiol supplement on the telomerase activity and DNA damage in cardiac
stem cells (CSCs) from healthy female mice. The telomerase activity and DNA damage in CSCs were evaluated by
immunostaining analysis on the expression of TERT (A) and 53BP1 (B), respectively, after 3 days of culture with the
supplement of different concentrations of 17β-estradiol in the medium. Representative images (upper) and
quantitative data (lower) are shown. The nuclei were labeled with DAPI. Scale bar: 20 μm. Control: sham-operated
mice, Ovx: ovariectomized mice, LE2: ovariectomized mice received a low dose of 17β-estradiol (0.01 mg/60 days),
HE2: ovariectomized mice received a high dose of 17β-estradiol (0.18 mg/60 days). All data are mean±SD from 3
independent experiments (n = 3 for each group). �P<0.05, ��P<0.01, ���P<0.001, ����P<0.0001.
https://doi.org/10.1371/journal.pone.0245166.g005
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induced changes in CSCs could be effectively recovered by the replacement with E2 at either
low or high doses. The benefits of E2 supplement to CSCs were also clearly indicated by various
in vitro evaluations.
Previous study by Tang et al. has demonstrated the potent regenerative effects of the CSC-
derived c-kit-positive cells through paracrine mechanisms [40]. It has also been reported the
enhanced cardio-protective effects of CSCs with E2 treatment [28]. ERα has been highly
expressed on the newly proliferated post-infarct cardiac c-kit+ cells and this receptor stimu-
lated cellular proliferation through activation of the pro-survival PI3K/Akt signaling pathway
which enhanced the survival of adult cardiomyocytes following MI [17]. Agreed well with
these past studies, our data also clearly showed the benefit of E2 in CSCs.
Telomeres are specific DNA-protein components present at the chromosomal terminus of
mammalian cells. Telomeres elongation is necessary to prevent DNA damage and senescence
for allowing the proliferation of the cells. TERT is responsible for the telomeric replication and
maintaining their elongations [41–46]. Estrogen can increase the activity of telomerase
through up-regulation of TERT gene [47, 48]. It has been reported that estrogen deficiency
inhibits telomerase activity and decrease the proliferation of cells [49, 50]. Otherwise, aging
and pathological conditions have been found to decreases the number and quality of CSCs [51,
52]. Considering the pivotal role of estrogen on the maintenance of CSCs, the cardio-protec-
tive effects of estrogen may depend, at least partially on the dynamic regulation of CSCs. As we
only investigated the quality of CSCs from intact hearts of young mice, it is still unclear
whether and how estrogen mediates the CSCs to repair a damaged heart, especially in aged
individuals and patients complicated with other clinical pathophysiological conditions.
There are several limitations to this study. First, we only used female mice for experiments
and did not measure the E2 levels in mice. Although the bioassay method (e.g. uterine weight)
may help to monitor the long-term effects of estrogen replacement using the estradiol-sus-
tained-release E2 pellets, it is asked to identify the optimal dose of E2 supplementation to keep
the estrogen at a physiological level for mice received ovariectomy. Second, the adverse effects
of high-dose estrogen on other organs needed to be evaluated. Third, we did not measure the
cardiac hemodynamics or the cardiac function using a damaged heart as an experimental
model, and the telomerase activity was only identified by immunostaining on the expression
of TERT. Otherwise, we did not try to further identify the underlying molecular mechanisms
on how estrogen maintaining the quality of CSCs.
In summary, our data indicated the potential role of estrogen in maintaining the quality of
CSCs, which may provide a novel insight into the cardio-protective effects of estrogen. Uncov-
ering the relevant molecular mechanisms may help to develop specific pharmacological com-
pounds that selectively target the estrogen receptors for the treatment/prevention of
postmenopausal cardiovascular diseases.
Supporting information
S1 Fig. Uterine weight of mice. Uterine weight was measured 2 months after treatments. Con-
trol: sham-operated mice, Ovx: ovariectomized mice, LE2: ovariectomized mice supplemented
with low dose of 17β-estradiol (0.01 mg/60 days), HE2: ovariectomized mice supplemented
with high dose of 17β-estradiol (0.18 mg/60 days). n = 3 for each group. All data are
mean ± SD from 3 independent experiments. �P<0.05. The statistical significance was deter-
mined by one-way analysis of variance (ANOVA), followed by Tukey’s test as a post compari-
son between groups (GraphPad Prism).
(JPG)
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S1 Table. In vivo raw data.
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